1月15日，益方生物跌5.1%，截至发稿，报30.12元/股，成交3.34亿元，换手率2.59%，总市值174.20亿 元。 资料显示，益方生物科技(上海)股份有限公司位于中国(上海)自由贸易试验区李冰路67弄4号210室,香港 湾仔皇后大道东183号合和中心46楼，成立日期2013年1月11日，上市日期2022年7月25日，公司主营业 务涉及创新药物的研发、生产和销售。主营业务收入构成为：技术授权和技术合作收入100.00%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 从基金十大重仓股角度 数据显示，富国基金旗下1只基金重仓益方生物。富国生物医药科技混合型A（006218）三季度减持 13.03万股，持有股数54.23万股，占基金净值比例为3.11%，位居第九大重仓股。根据测算，今日浮亏 损失约87.86万元。 富国生物医药科技混合型A（006218）成立日期2019年3月12日，最新规模4.86亿。今年以来收益 11.48%，同类排名638/ ...

1月13日，益方生物涨5.36%，截至发稿，报34.40元/股，成交2.15亿元，换手率1.54%，总市值198.95亿 元。 资料显示，益方生物科技(上海)股份有限公司位于中国(上海)自由贸易试验区李冰路67弄4号210室,香港 湾仔皇后大道东183号合和中心46楼，成立日期2013年1月11日，上市日期2022年7月25日，公司主营业 务涉及创新药物的研发、生产和销售。主营业务收入构成为：技术授权和技术合作收入100.00%。 国投瑞银上证科创板200指数发起式A（023518）成立日期2025年3月18日，最新规模4526.48万。今年以 来收益15.22%，同类排名292/5517；成立以来收益56.55%。 国投瑞银上证科创板200指数发起式A（023518）基金经理为赵建、钱瀚。 截至发稿，赵建累计任职时间12年113天，现任基金资产总规模76.12亿元，任职期间最佳基金回报 181.16%， 任职期间最差基金回报-88.73%。 钱瀚累计任职时间2年153天，现任基金资产总规模10.54亿元，任职期间最佳基金回报52.25%， 任职期 间最差基金回报-5.53%。 风险提示：市场有风险，投资需谨 ...

Investment Rating - The report maintains a rating of "Overweight" for the pharmaceutical and biotechnology sector [4]. Core Insights - The brain-computer interface (BCI) sector is showing active performance, with recommendations to continue monitoring thematic opportunities. The global BCI market is projected to reach USD 7.63 billion by 2029, indicating a rapidly opening blue ocean market [20][21]. - The investment strategy emphasizes the importance of clinical value in the pharmaceutical sector, focusing on innovative drug chains and medical devices. Key recommendations include companies involved in BD overseas acceleration and high-end medical devices [23][25]. Summary by Sections Market Review - The A-share pharmaceutical and biotechnology index rose by 7.81%, outperforming the CSI 300 index by 5.03 percentage points and the ChiNext index by 2.10 percentage points, ranking 6th among 31 sub-industries. The Hong Kong Hang Seng Healthcare Index increased by 10.26%, surpassing the Hang Seng Index by 11.57 percentage points [15][9]. R&D Progress - Recent clinical applications include IMM2510 and Tida-Paclitaxel from Yiming Anke, with ongoing Phase III trials for Tiengoteini from Yaokang and Phase II trials for SYS6017 from Shiyao Group [28]. Key Recommendations - Focus on three categories of companies: 1. Medical scene integrators (e.g., Xiangyu Medical, Weisi Medical) benefiting from insurance payment integration and existing rehabilitation needs [21]. 2. Leaders in invasive/semi-invasive technologies (e.g., Xinwei Medical, Jieti Medical) with significant technological advantages [21]. 3. Full-process support providers (e.g., Meihua Medical, Sanbo Neuroscience) focusing on high-certainty segments like supply chain production and clinical development [21]. Financial Forecasts and Valuations - Key companies and their projected earnings per share (EPS) and price-to-earnings (PE) ratios for 2024-2026 include: - Tianzhili: EPS of 0.64, PE of 24 [3]. - Innovent Biologics: EPS of -0.06, PE of NA [3]. - WuXi AppTec: EPS of 3.27, PE of 30 [3]. - Mindray Medical: EPS of 9.62, PE of 21 [3]. - Weisi Medical: EPS of 1.06, PE of 62 [3]. Policy and Industry Resonance - The report highlights a structural shift in domestic policies favoring innovative drugs, with a focus on clinical value and the potential for valuation recovery in the pharmaceutical sector. The report suggests that the investment attractiveness of the pharmaceutical sector will continue to grow [23][24].

Group 1 - The A-share market experienced a rebound, with the Shanghai Composite Index reaching 4100 points for the first time in 10 years as of January 9 [1] - The AI-focused ETF, Huatai-PB (589560), saw a 2% increase, indicating strong investor interest in AI technology [1][5] - Major stocks in the AI sector, such as Zhongke Xingtou and Chip Origin, reported significant gains, with Zhongke Xingtou rising over 8% [5] Group 2 - UBS Securities noted a growing interest from international investors in Chinese AI technology companies, suggesting the emergence of trillion-dollar companies is only a matter of time [3] - A recent policy document from eight departments outlined goals for AI development, aiming for secure supply of core technologies and maintaining a leading position in the industry by 2027 [3] - The policy emphasizes enhancing AI applications in manufacturing through innovation, capability improvement, and product development [4] Group 3 - The focus of AI policy is shifting from "digital transformation" to "AI+", aiming to leverage advanced technologies for complex decision-making and innovation [4] - The policy framework includes promoting computational power and algorithm supply tailored to industrial scenarios, supporting the development of AI applications across various sectors [4] - The market consensus on AI industry trends is strong, with expectations for continued growth in AI infrastructure and applications leading up to 2026 [6] Group 4 - The investment strategy suggests focusing on domestic computational power and AI applications, particularly in the internet and media sectors, as they present high valuation and growth potential [6][7] - The AI industry is expected to benefit from a combination of policy support, technological advancements, and stable fundamental growth, creating a favorable environment for investment [7]

Core Viewpoint - The trend of A-share companies "going south" to list on H-shares is gaining momentum in early 2026, driven by a combination of policy support, financing needs, and internationalization strategies [1][2][3] Group 1: Companies Going Public - Six A-share companies, including Jucheng Co., Penghui Energy, and Zhengtai Electric, have announced plans for H-share listings from January 1 to January 8, 2026 [1] - Four additional companies, including Jingwang Electronics and Yifang Bio, have submitted prospectuses to the Hong Kong Stock Exchange [1] - The trend is primarily led by technology companies, with a focus on sectors such as semiconductor design, energy storage, and smart mobility [1] Group 2: Market Dynamics - The 2026 "southbound" trend is a continuation of the 2025 A+H listing boom, with a significant increase in active listing applications in Hong Kong [2] - In 2025, 19 A-share companies listed on the Hong Kong market, raising a total of approximately 139.99 billion HKD, nearly half of the total IPO amount for the year [2] - The average time for A+H listings in 2025 was reported to be 4 to 6 months, with the fastest taking only about 3 months [2] Group 3: Strategic Motivations - A-share companies are pursuing H-share listings to raise funds for global expansion and enhance their competitive position in international markets [3][4] - Companies like Jucheng Co. and Penghui Energy emphasize that listing in Hong Kong will help them build a diversified capital operation platform and support overseas business development [3] - The need for substantial foreign currency funding for overseas production and supply chain establishment is a key driver for these companies [4] Group 4: Regulatory Environment - The favorable regulatory environment, including cooperation measures between mainland and Hong Kong regulatory bodies, has made cross-border listings more feasible [4] - The Chinese Securities Regulatory Commission has expressed support for leading mainland companies to list in Hong Kong, facilitating a quicker approval process for qualified firms [4] - The current valuation of Hong Kong stocks is perceived to be lower than that of A-shares, prompting some companies to accept lower valuations to secure international funding and prepare for stricter overseas disclosure standards [4] Group 5: Market Expectations - The IPO market in Hong Kong is expected to perform well in 2026, with projections of over 300 billion HKD in IPO scale and 150 to 200 projects [4] - The growth in the MSCI China Index's earnings is anticipated to reach 14% or higher, driven by sectors such as high-end manufacturing and companies with global expansion capabilities [4]

Core Viewpoint - The innovative drug ETF Tianhong (517380) has seen significant trading activity and growth, indicating a strong interest in the innovative drug sector, which is experiencing a historic surge in IPOs and commercialization efforts [1][4]. Group 1: ETF Performance - As of January 8, 2026, the innovative drug ETF Tianhong (517380) recorded a transaction volume of 18.58 million yuan, with the tracked index HSSSHID rising by 0.92% [1]. - The latest scale of the innovative drug ETF Tianhong reached 1.578 billion yuan, with a total of 1.962 billion shares, both marking all-time highs since its inception [2]. - The net inflow of funds into the innovative drug ETF Tianhong was 89.42 million yuan, the highest since April 2025 [3]. Group 2: Market Trends - The innovative drug sector is experiencing a "volume and price increase" opportunity, with the top ten constituent stocks of the ETF heavily weighted towards leading companies like WuXi AppTec and HengRui Medicine, benefiting from a surge in business development (BD) transactions and breakthroughs in AI drug development [3]. - In 2025, the innovative drug sector achieved a historic explosion, with over 30 biotech companies successfully listed in A-shares and Hong Kong, and more than 50 companies awaiting approval, reflecting unprecedented capital activity [4]. - The sector has transitioned from mere speculation to substantial commercialization, becoming a benchmark sector with both growth potential and certainty in the current bull market [4]. Group 3: Institutional Insights - Southwest Securities noted that in early 2025, Hong Kong companies began achieving BD, leading to a rise in the innovative drug sector; a government report in March emphasized support for innovative drugs and medical devices, further boosting A-share performance [5]. - The sector experienced a significant price increase following a major BD deal worth 1.25 billion USD in May, but faced a high-level adjustment by the end of the third quarter [5]. - The firm predicts that in 2026, the innovative drug sector will shift from a broad rally to a selective stock market [5].

证券代码：688382 证券简称：益方生物 公告编号：2026-002 益方生物科技（上海）股份有限公司 董事会薪酬与考核委员会 关于公司 2025 年限制性股票激励计划激励对象名单 的审核意见及公示情况说明 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 益方生物科技（上海）股份有限公司（以下简称"公司"）于 2025 年 12 月 19 日召开第二届董事会 2025 年第九次会议，审议通过《关于<益方生物科技 （上海）股份有限公司 2025 年限制性股票激励计划（草案）>及其摘要的议 案》等议案。根据《上市公司股权激励管理办法》（以下简称"《管理办法》"） 等相关规定，公司对 2025 年限制性股票激励计划（以下简称"本次激励计 划"）激励对象名单在公司内部进行了公示。公司董事会薪酬与考核委员会结合 公示情况对拟激励对象进行了核查，相关公示及核查情况如下： 一、公示情况及核查方式 （一）公示情况 2025 年 12 月 19 日，公司召开第二届董事会 2025 年第九次会议，审议通过 《关于<益方生物科技（上海）股份有 ...

Group 1 - The A-share market saw a collective rise in innovative drug concept stocks on January 7, with notable gains including a 20% increase for Beibete-U and over 17% for Yinos. [1] - Other significant performers included Chengdu XianDao with a 13% rise, and Panlong Pharmaceutical reaching a 10% increase. [1] - Additional stocks such as Yangguang Nuohuo and Zhaoyan New Drug also experienced gains exceeding 9% and 7% respectively. [1] Group 2 - The table lists various stocks with their respective codes, showing percentage increases, total market capitalization, and year-to-date performance. [2] - Beibete-U (688759) had a market cap of 18.6 billion with a year-to-date increase of 42.46%. [2] - Yinos (688710) reported a market cap of 7.611 billion and a year-to-date increase of 22.29%. [2] - Chengdu XianDao (688222) had a market cap of 12.2 billion and a year-to-date increase of 29.59%. [2] - Other stocks listed include Panlong Pharmaceutical (002864) with a market cap of 3.706 billion and a year-to-date increase of 13.07%, and Yangguang Nuohuo (688621) with a market cap of 8.188 billion and a year-to-date increase of 17.63%. [2]

格隆汇1月7日｜A股市场创新药概念股集体上涨，其中，必贝特-U 20CM涨停，益诺思涨超17%，成都 先导涨超13%，盘龙药业10CM涨停，阳光诺和涨超9%，昭衍新药、前沿生物、迈威生物、益方生物涨 超7%，悦康药业涨超6%。 | 代码 | 名标 | | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | 688759 | 1 必贝特-U | | 20.00 | 186亿 | 42.46 | | 688710 | 益裙思 | | 17.14 | 76.11亿 | 22.29 | | 688222 | 成都先导 | 1 | 13.48 | 122亿 | 29.59 | | 002864 | 盘龙药业 | | 10.00 | 37.06亿 | 13.07 | | 688621 | 阳光诺和 | | 9.28 | 81.88 Z | 17.63 | | 603127 | 昭衍新药 | 1 | 7.83 | 311亿 | 18.42 | | 688221 | 前沿生物-l * | | 7.72 | 2665.06 | 33.68 | | 68 ...

Core Viewpoint - Yifang Biopharma has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange, focusing on its innovative drug pipeline and ongoing R&D investments [2][4]. Group 1: Financial Performance - In the first three quarters of 2025, the company reported revenue of 30.89 million yuan and a net loss of 181 million yuan, with R&D expenses reaching 190 million yuan [2]. - Since its IPO on the Sci-Tech Innovation Board in 2022, Yifang Biopharma has accumulated losses exceeding 1.189 billion yuan, indicating a heavy reliance on R&D funding [2]. Group 2: Product Pipeline - The company has two commercialized drugs, BPI-D0316 and D-1553, which are included in the national medical insurance directory, generating revenue through external licensing [2]. - Yifang Biopharma is developing core drugs D-2570 and D-0502, with D-2570 targeting conditions like psoriasis and ulcerative colitis, and potential future applications in other diseases [3]. Group 3: Market Dynamics - The price of BPI-D0316 significantly decreased after being included in the medical insurance directory, dropping from approximately 6000 yuan to between 2800 and 2862 yuan, a reduction of 52%-53%, impacting the company's revenue expectations [3]. - The market for psoriasis is expected to grow, indicating potential for future revenue despite current pricing pressures [3]. Group 4: Fundraising Purpose - The funds raised from the Hong Kong listing will be allocated to the clinical development of core products D-2570 and D-0502 to accelerate their R&D processes [4].